Enliven Therapeutics, Inc.
$46.41
▲
2.75%
2026-04-21 06:37:01
www.enliventherapeutics.com
NMS: ELVN
Explore Enliven Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$2.88 B
Current Price
$46.41
52W High / Low
$48.53 / $14.79
Stock P/E
—
Book Value
$7.73
Dividend Yield
—
ROCE
-26.04%
ROE
-26.95%
Face Value
—
EPS
$-1.83
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
60
Beta
0.49
Debt / Equity
0.09
Current Ratio
28.66
Quick Ratio
28.66
Forward P/E
-17.84
Price / Sales
—
Enterprise Value
$2.25 B
EV / EBITDA
-18.83
EV / Revenue
—
Rating
Strong Buy
Target Price
$51
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Ultragenyx Pharmaceutical Inc. | $25.06 | — | $2.39 B | — | -46.6% | -6.08% | $42.37 / $18.29 | $-0.83 |
| 2. | FibroBiologics, Inc. | $1.53 | — | $5.37 M | — | -211.82% | -4.19% | $30.6 / $1.03 | $1.85 |
| 3. | Kezar Life Sciences, Inc. | $7.29 | — | $53.74 M | — | -74.59% | -59.93% | $7.55 / $3.53 | $9.56 |
| 4. | Telomir Pharmaceuticals, Inc. | $1.48 | — | $49.85 M | — | -178.22% | -3.18% | $3.1 / $1.05 | $0.17 |
| 5. | Canton Strategic Holdings, Inc. | $3.51 | — | $194.33 M | — | -3.9% | -17.99% | $9.08 / $1.05 | $10.72 |
| 6. | Celldex Therapeutics, Inc. | $34.38 | — | $2.7 B | — | -54.02% | -40.62% | $35.29 / $17.45 | $7.92 |
| 7. | Artiva Biotherapeutics, Inc. | $13.39 | — | $310.19 M | — | -76.21% | -56.55% | $13.2 / $1.47 | $4.53 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -34.28 M | -25.1 M | -28.58 M | -31.69 M | -26.9 M | — |
| Net Profit | -29.67 M | -20.15 M | -25.34 M | -28.54 M | -23.18 M | — |
| EPS in Rs | -0.5 | -0.34 | -0.42 | -0.48 | -0.39 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -119.66 M | -104.55 M | -83.53 M | -38.79 M |
| Net Profit | -103.69 M | -89.02 M | -71.58 M | -37.66 M |
| EPS in Rs | -1.73 | -1.49 | -1.2 | -0.63 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 476.17 M | 325.76 M | 271.87 M | 83.3 M |
| Total Liabilities | 16.57 M | 15.91 M | 25.96 M | 160.12 M |
| Equity | 459.6 M | 309.85 M | 245.91 M | -76.83 M |
| Current Assets | 474.88 M | 318.13 M | 266.15 M | 77.75 M |
| Current Liabilities | 16.57 M | 15.91 M | 25.89 M | 9.71 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -70.3 M | -73.19 M | -61.27 M | -32.08 M |
| Investing CF | -173.84 M | -36 M | -148.41 M | -0.61 M |
| Financing CF | 218.87 M | 133.16 M | 234.29 M | -1.8 M |
| Free CF | -70.46 M | -73.24 M | -61.42 M | -32.69 M |
| Capex | -0.16 M | -0.04 M | -0.15 M | -0.61 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -24.36% | -90.07% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.